TGen's platform.org social media study has been nominated for an international social impact award
Transformative AI-Driven Research Project Aims to Cure Alzheimer's
The Translational Genomics Research Institute (TGen) has unveiled an innovative online research project, Our Platform, which is making significant strides in understanding and ultimately curing Alzheimer's disease. This cutting-edge initiative has been recognised with a social-impact award, marking its importance in the fight against this socioeconomic epidemic.
Our Platform is an AI-based digital tool that integrates large-scale genetics, genomics, multi-omics, and clinical data through advanced artificial intelligence and machine learning methods. The platform's goal is to identify causal mechanisms of Alzheimer's, particularly early-onset forms, and facilitate data sharing, analysis, and collaboration among researchers worldwide.
The project's approach involves using deep learning and multiple kernel learning models to identify rare coding and non-coding genetic variants linked to Alzheimer's. It also employs a Bayesian framework to analyse gene regulatory networks related to Alzheimer's in a cell-type specific manner. By leveraging genetic and clinical data from diverse populations, the platform aims to improve precision and inclusivity in Alzheimer's research.
With Our Platform, researchers are empowered with an intelligent, multimodal AI framework to analyse complex datasets. This accelerates the identification of new drug targets, which could lead to earlier diagnosis and more effective treatments tailored to a patient's genetic profile. This method supports a precision medicine approach aimed at ultimately finding a cure for Alzheimer's disease.
Alzheimer's disease is a significant issue, affecting over 5 million Americans and being the 6th leading cause of death in the U.S. The disease costs the nation over $200 billion annually to treat. TGen, a Phoenix, Arizona-based non-profit organization, is dedicated to conducting groundbreaking research with life-changing results, focusing on cancer, neurological disorders, and diabetes.
TGen collaborates with scientists and medical communities worldwide to make a substantial contribution to patient care. Nearly 28,000 volunteers have already taken part in TGen's Our Platform study, with a goal of gathering results from as many as 1 million participants.
The CLASSY Awards, the largest social impact awards ceremony in the United States, will be held on May 3, 2014, at the Marriott Marquis in San Diego. Top leaders from the social sector will convene at the CLASSY Awards to collaborate on solving social problems. The CLASSY Awards recognises champions of social progress, and this year, TGen's Our Platform is a finalist for this prestigious award.
For more information about TGen and Our Platform, visit www.tgen.org. For press inquiries, contact Steve Yozwiak, TGen Senior Science Writer, at [email protected] or 602-343-8704.
- The AI-based digital tool, Our Platform, developed by the Translational Genomics Research Institute (TGen), is a significant stride in neurogenomics, integrating large-scale genetics, genomics, and clinical data to understand and potentially cure Alzheimer's disease.
- Our Platform's aim is to identify causal mechanisms of Alzheimer's, including early-onset forms, and contribute to mental health and neurological disorder research, with a focus on Alzheimer's disease, by leveraging genetic and clinical data from diverse populations.
- The health-and-wellness sector can benefit from the precision medicine approach supported by Our Platform, as it accelerates the identification of new drug targets for Alzheimer's disease, potentially leading to earlier diagnosis and more effective treatments tailored to a patient's genetic profile.
